WHO-GMP Certified Facility

Instagram Facebook-f Linkedin
icon

WHO-GMP Certified Facility

Inquire Now

Silodosin

CPPL / Product / Silodosin

Silodosin

silodosin

CAS No.: 160970-54-7
Category: Alpha-1 Adrenergic Receptor Blocker
Molecular Formula: C₂₅H₃₂F₃N₃O₄
Molecular Weight: 495.53 g/mol
Synonyms: KMD-3213, KAD-3213

Description:

Silodosin is a selective alpha-1 adrenergic receptor antagonist primarily targeting the α1A receptor subtype. It is used to improve urinary symptoms associated with benign prostatic hyperplasia (BPH) by relaxing smooth muscle in the prostate and lower urinary tract.

Silodosin has a high affinity for the α1A subtype of alpha-1 adrenergic receptors, which are predominantly associated with the prostate, bladder neck, bladder base, prostatic capsule and prostatic urethra.

Applications

Silodosin is primarily used in urological and pharmaceutical applications, particularly for the management and research of lower urinary tract symptoms associated with BPH.

Key Applications

  • Benign Prostatic Hyperplasia: Used for the treatment of signs and symptoms associated with BPH.
  • Urological Research: Used to study alpha-1 adrenergic receptor signaling in the lower urinary tract.
  • Prostate Research: Investigated for its effects on prostate and bladder-neck smooth muscle.
  • Lower Urinary Tract Studies: Used in research involving urinary flow and bladder outlet resistance.
  • Alpha-1 Receptor Research: Used as a selective α1A receptor antagonist in pharmacological studies.
  • Pharmaceutical Development: Used as an API/reference compound in formulation and analytical development.

Silodosin’s selective activity at α1A receptors helps relax smooth muscle in the prostate and bladder outlet, improving urinary flow and reducing BPH symptoms.

Product Specifications

Silodosin is a pharmacologically active alpha-adrenergic antagonist and should be handled according to the applicable SDS and pharmaceutical safety procedures.

Handling Precautions

  • Avoid inhalation of powder.
  • Avoid direct contact with eyes and skin.
  • Use appropriate gloves and protective eyewear.
  • Handle in a well-ventilated area.
  • Minimize dust formation.
  • Keep the container tightly closed.
  • Wash hands thoroughly after handling.
  • Avoid eating, drinking or smoking while handling.

Pharmaceutical Safety

Silodosin can cause postural hypotension and dizziness, particularly around treatment initiation. Patients should be appropriately cautioned about activities such as driving or operating machinery until they know how the medicine affects them.

Silodosin is also contraindicated in patients with severe renal or hepatic impairment according to product labeling, so pharmaceutical use should follow approved prescribing information.

Mechanism of Actions

Silodosin works primarily by selectively blocking post-synaptic α1A adrenergic receptors.

1. α1A Adrenergic Receptor Blockade

Silodosin binds with high affinity to the α1A subtype of alpha-1 adrenergic receptors. These receptors are found in the prostate, bladder neck, bladder base, prostatic capsule and prostatic urethra.

2. Smooth Muscle Relaxation

Blocking α1A receptors reduces adrenergic smooth-muscle tone in the prostate and bladder outlet.

3. Improved Urinary Flow

The resulting relaxation decreases resistance to urine flow and helps reduce lower urinary tract symptoms associated with BPH.

Simplified pathway:

Silodosin → α1A receptor blockade → prostate/bladder-neck smooth muscle relaxation → reduced urinary resistance → improved urine flow

FAQs

1. What is Silodosin?

Silodosin is a selective α1A adrenergic receptor antagonist primarily used to treat urinary symptoms associated with benign prostatic hyperplasia.

2. What is the CAS number of Silodosin?

The CAS number is 160970-54-7.

3. What is the molecular formula of Silodosin?

The molecular formula is C₂₅H₃₂F₃N₃O₄.

4. What is the molecular weight of Silodosin?

The molecular weight is approximately 495.53 g/mol.

5. What is Silodosin used for?

Silodosin is primarily used for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH).

6. How does Silodosin work?

Silodosin selectively blocks post-synaptic α1 adrenergic receptors, particularly α1A receptors, causing smooth muscle relaxation in the prostate and bladder outlet.

7. What is the main receptor targeted by Silodosin?

Silodosin has high affinity for the α1A adrenergic receptor subtype.

8. What is the physical form of Silodosin?

Silodosin is described as a white to pale yellowish-white powder.

9. How should Silodosin be stored?

Protect Silodosin from light and moisture and store under controlled room-temperature conditions, subject to the specific product’s validated storage requirements.

10. What are the development codes for Silodosin?

Silodosin has been associated with the development codes KMD-3213 and KAD-3213.

Related Products
Request Sample